{
    "clinical_study": {
        "@rank": "161393", 
        "arm_group": {
            "arm_group_label": "POL6326", 
            "arm_group_type": "Experimental", 
            "description": "POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin"
        }, 
        "brief_summary": {
            "textblock": "POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to,\n      on the day of and on days after treatment with eribulin. Different doses and dosing\n      frequencies will be investigated"
        }, 
        "brief_title": "Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed invasive cancer of the breast.\n\n          -  Presence of at least one measurable lesion per RECIST 1.1 criteria\n\n          -  Stage IV disease by AJCC criteria (7th edition).\n\n          -  HER2 negative (IHC 0,1 or FISH HER2:CEP17 ratio < 2.0)\n\n          -  Must have had treatment with at least 2 but no more than 3 previous regimens in the\n             metastatic setting. Previous treatment must have included an anthracycline and taxane\n             in either the adjuvant or metastatic setting.\n\n          -  At least 21 days from the completion of any previous cytotoxic chemotherapy or\n             biological therapy at time of initiation of POL6326.\n\n          -  ECOG performance status < 2\n\n        Exclusion Criteria:\n\n          -  Previously received eribulin.\n\n          -  Peripheral neuropathy > Grade 2.\n\n          -  Receipt of any other investigational agent within the 28 days prior to Day 1.\n\n          -  Receipt of colony stimulating factor filgrastim, pegfilgrastim, or sargramostim\n             within 14 days prior to Day 1.\n\n          -  Radiation therapy within the 14 days prior to Day 1.\n\n          -  Severe concurrent illness or psychiatric illness/social situation that would limit\n             compliance with study requirements.\n\n          -  History of other malignancy \u2264 5 years previous with the exception of basal cell or\n             squamous cell carcinoma of the skin which were treated with local resection only or\n             carcinoma in situ of the cervix.\n\n          -  Pregnant or breastfeeding.\n\n          -  Known HIV positivity on combination antiretroviral therapy; these patients are at\n             increased risk of lethal infections when treated with marrow-suppressive therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837095", 
            "org_study_id": "POL-7"
        }, 
        "intervention": {
            "arm_group_label": "POL6326", 
            "description": "POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin", 
            "intervention_name": "POL6326", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Overall survival", 
            "Progression free survival"
        ], 
        "lastchanged_date": "November 28, 2013", 
        "location": {
            "contact": {
                "email": "fademuyi@dom.wustl.edu", 
                "last_name": "Foluso O Ademuyiwa, M.D.", 
                "phone": "314-362-7201"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine, Division of Oncology"
            }, 
            "investigator": {
                "last_name": "Foluso O Ademuyiwa, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "fademuyi@dom.wustl.edu", 
            "last_name": "Foluso O Ademuyiwa, M.D.", 
            "phone": "(314) 362-7201"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence and severity of adverse events and serious adverse events of the combination of POL6326 and eribulin when compared to the adverse event profile of eribulin alone", 
            "measure": "Safety and tolerability of POL6326 in combination with eribulin in patients with metastatic breast cancer", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Determination of the complete response (CR) and partial response (PR) in patients treated with the combination of POL6326 and eribulin", 
            "measure": "Response rate of treatment with POL6326 and eribulin in patients with metastatic breast cancer", 
            "safety_issue": "No", 
            "time_frame": "12-24 months"
        }, 
        "source": "Polyphor Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Polyphor Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}